SCHEMBL18702702

SCHEMBL18702702

CCOC(=O)c1cc2cc(Cl)cc(C)c2nc1-c1cc2ccccc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 3/20 0.53
▸ JAK3 P52333 3/20 0.53
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ KDM4E B2RXH2 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ RAB9A P51151 4/20 0.44
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 4/20 0.42
▸ MIF P14174 1/20 0.42
▸ PFKFB3 Q16875 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29503023 1.00 JAK2 (0.53) JAK2JAK3TP53MAPTCASP3
SCHEMBL18702712 0.86 MAOB (0.45) JAK2JAK3MAPTKDM4EALDH1A1
SCHEMBL29503041 0.86 MAOB (0.45) JAK2JAK3MAPTKDM4EALDH1A1
SCHEMBL25744700 0.75 MAPT (0.53) JAK2JAK3TP53MAPTCASP3
SCHEMBL2314723 0.75 MAOB (0.48) TP53MAPTKDM4EALDH1A1TSHR
SCHEMBL18496766 0.74 MAPT (0.59) JAK2JAK3TP53MAPTCASP3
SCHEMBL2313121 0.73 MAOB (0.52) TP53MAPTKDM4EALDH1A1HSD17B10
SCHEMBL6243624 0.71 KDM4E (0.80) KDM4EALDH1A1HSD17B10TSHRMAOA
SCHEMBL8007129 0.70 KDM4E (0.58) JAK2JAK3TP53MAPTCASP3
SCHEMBL23067859 0.69 JAK2 (0.53) JAK2JAK3TP53MAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220227739-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2022-07-21 — — US disclosed
CN-108430994-B Compounds, compositions and methods for modulating CFTR 蛋白质平衡治疗股份有限公司 2022-04-12 — — CN disclosed
US-11136313-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2021-10-05 — — US disclosed
EP-3359536-B1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS INC (US) 2021-08-04 — — EP disclosed
US-20200385365-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2020-12-10 — — US disclosed
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-02-04 — — US disclosed
US-20180291006-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. 2018-10-11 — — US disclosed
WO-2017062581-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136313-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G JAK2 3732/4885JAK3 4533/4885TP53 1592/4885
US-20200385365-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G JAK2 3732/4885JAK3 4533/4885TP53 1592/4885
US-20220227739-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G JAK2 3732/4885JAK3 4533/4885TP53 1592/4885
US-10550106-B2 Compounds, compositions, and methods for modulating CFTR CFTR, SCNN1B, SCNN1G JAK2 3732/4885JAK3 4533/4885TP53 1592/4885
US-20180291006-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR CFTR, SCNN1B, SCNN1G JAK2 3732/4885JAK3 4533/4885TP53 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback